Two fusion enzymes consisting of uridine diphosphogalactose 4-epimerase (UDP-galactose 4-epimerase, EC 5.1.3.2) and ␣1,3-galactosyltransferase (EC 2.4.1.151) with an N-terminal His 6 tag and an intervening threeglycine linker were constructed by in-frame fusion of the Escherichia coli galE gene either to the 3 terminus (f1) or to the 5 terminus (f2) of a truncated bovine ␣1,3-galactosyltransferase gene, respectively. Both fusion proteins were expressed in cell lysate as active, soluble forms as well as in inclusion bodies as improperly folded proteins. Both f1 and f2 were determined to be homodimers, based on a single band observed at about 67 kDa in SDS-polyacrylamide gel electrophoresis and on a single peak with a molecular mass around 140 kDa determined by gel filtration chromatography for each of the enzymes. Without altering the acceptor specificity of the transferase, the fusion with the epimerase changed the donor requirement of ␣1,3-galactosyltransferase from UDP-galactose to UDP-glucose and decreased the cost for the synthesis of biomedically important Gal␣1, 3Gal-terminated oligosaccharides by more than 40-fold. For enzymatic synthesis of Gal␣1,3Gal1,4Glc from UDP-glucose and lactose, the genetically fused enzymes f1 and f2 exhibited kinetic advantages with overall reaction rates that were 300 and 50%, respectively, higher than that of the system containing equal amounts of epimerase and galactosyltransferase. These results indicated that the active sites of the epimerase and the transferase in fusion enzymes were in proximity. The kinetic parameters suggested a random mechanism for the substrate binding of the ␣1,3-galactosyltransferase. This work demonstrated a general approach that fusion of a glycosyltransferase with an epimerase can change the required but expensive sugar nucleotide to a less expensive one.Oligosaccharides are attractive targets for the development of new pharmaceuticals because of their important roles in cell recognition, cell signaling, and other biological processes (1, 2). ␣-Gal 1 epitopes (Gal␣1,3Gal-terminated oligosaccharide sequences including di-, tri-, and pentasaccharides) have drawn increasing attention since it was discovered that the interaction of preexisting natural antibodies in human serum with this specific xenoactive oligosaccharide sequence on animal cells is the main cause of hyperacute rejection in xenotransplantation (3). ␣-Gal epitopes exist as glycolipids or glycoproteins on the cell surface of mammals other than humans, apes, and Old World Monkeys (4, 5). The unique enzyme responsible for the formation of the terminal glycoside bond in nature is UDP-Gal:Gal1,4GlcNHAc ␣1,3-galactosyltransferase (␣1,3GalT), a protein that is absent in humans due to mutational inactivation of the gene (6, 7). In contrast, humans produce a large amount of anti-Gal antibodies including IgG, IgM, and IgA isotypes (8).The discovery of the interaction of anti-Gal and ␣-Gal epitopes has led to experimental attempts to overcome hyperacute rejection by either depleting the recip...